ADORA2A and Alzheimer disease: Although there is evidence suggesting that A2AR blockade restrains astrocyte reactivity (Hindley et al., 1994; Brambilla et al., 2003; Minghetti et al., 2007, see also Cunha, 2016), the pathophysiological impact of astrocytic A2AR upsurge in reactive astrocytes in conditions of brain disorders, in particular of AD, remains to be defined.